A Study of RD06-04 in Patients With Active Autoimmune Diseases

NCT06548620 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped R\&D strategy adjustment

Conditions

SLE
Sclerosis
ANCA Associated Vasculitis
IIM
SS
MS
NMO Spectrum Disorder
MG

Interventions

DRUG: RD06-04 cell infusion

Sponsor

Nanjing Bioheng Biotech Co., Ltd.